NASDAQ:OABI

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Retrieved on: 
Lundi, juin 3, 2024
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Hook effect, Multimedia, Light, Journal, Molecular biology, Engineering, Immunology, Immunoglobulin G, Chicken, Asian literature, Vertebrate, Vaccine

OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240603162111/en/
    Image rendering of OmniAb’s OmnidAb™, a stabilized fully human heavy chain only single domain antibody (Graphic: Business Wire)
    sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks for antibody discovery.
  • “Our team’s published data provided the foundational work supporting the feasibility of the Company’s next-generation transgenic chicken OmnidAb that produces fully human stabilized sdAbs.

OmniAb to Participate in the Jefferies Global Healthcare Conference

Retrieved on: 
Lundi, mai 20, 2024
Biotechnology, Pharmaceutical, Health, Conference, Marriott Marquis

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.
  • Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors.
  • A live and archived webcast of the presentation will be available in the Investors section of OmniAb’s website.

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

Retrieved on: 
Mercredi, mai 15, 2024
Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Other Science, Other Technology, Research, Artificial Intelligence, Science, Asian literature, Amino acid, Boston, Machine learning, Omni Hotels & Resorts, Artificial intelligence, AI, Animal, Cell, Monoclonal antibody, Multimedia, Antibody, Biology, Vaccine

OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel.

Key Points: 
  • OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel.
  • “The synergy between xPloration, OmniFlic, OmniClic, and OmniDeep enables new bispecific antibody discovery workflows for our partners.
  • With xPloration, OmniAb’s scientific team screened tens of millions of cells and recovered thousands of unique antibody sequences.
  • For more information about OmniAb’s proprietary technologies, please visit www.omniab.com or contact our business development team at [email protected] .

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Jeudi, mai 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

OmniAb to Participate in Five Investor Conferences in May

Retrieved on: 
Mercredi, mai 1, 2024
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Conference, Cryptocurrency

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May.
  • Management will participate in a fireside chat on Wednesday, May 15th at 11:30 a.m. Eastern time and will hold one-on-one meetings with investors.
  • Management will participate in a fireside chat on Monday, May 20th at 9:30 a.m. Eastern time and will hold one-on-one meetings with investors.
  • Management will participate in a fireside chat on Thursday, May 30th at 8:00 a.m. Central time and will hold one-on-one meetings with investors.

OmniAb to Report First Quarter 2024 Financial Results on May 9

Retrieved on: 
Lundi, avril 22, 2024
Technology, Research, Genetics, Biotechnology, Radiology, Health, Pharmaceutical, Science, Artificial Intelligence

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Key Points: 

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Mercredi, mars 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Retrieved on: 
Lundi, février 26, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Key Points: 

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

OmniAb to Participate in Two Investor Conferences in March

Retrieved on: 
Mardi, février 20, 2024
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Fontainebleau Miami Beach, Conference, Cryptocurrency

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March.
  • TD Cowen 44th Annual Healthcare Conference, March 4-6, 2024, at the Marriott Copley Place in Boston, MA.
  • Management will participate in a fireside chat on Monday, March 4th at 11:10 a.m. Eastern time and will be available for one-on-one meetings with investors.
  • Management will be hosting one-on-one meetings with the investors on Tuesday, March 12th.

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

Retrieved on: 
Jeudi, décembre 14, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Washington Marriott Marquis, ISCB Senior Scientist Award, Antibody, Senior, Therapy, Chicken, Hook effect, Epitope, Multimedia, Conference, Engineering, AI, Discovery system (AI research), Vaccine, Fine chemical

OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society .

Key Points: 
  • OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society .
  • This minimizes the need for downstream engineering and provides a functionally diverse immune repertoire that is unavailable from mammalian systems.
  • OmniAb is showcasing OmnidAb and its entire technology stack at the 2023 Antibody Engineering & Therapeutics Conference at booth #300 at the Marriott Marquis San Diego Marina.
  • OmniAb is leveraging its technology stack to offer partners new discovery workflows and optimization tools for existing discovery campaigns.